vaccine, japanese encephalitis


sanofi pasteur


Zuellig Pharma
Concise Prescribing Info
Live, attenuated, recombinant Japanese encephalitis virus (propagated in Vero cells)
Prophylaxis of Japanese encephalitis in individuals ≥9 mth.
Dosage/Direction for Use
Primary immunization Childn ≥9 mth 0.5 mL single SC inj. Booster dose Adult ≥18 yr No need for booster dose up to 5 yr after 1st vaccination. Childn 9 mth-17 yr 12-24 mth after primary vaccination.
Hypersensitivity to the vaccine or after previous inj. Postpone vaccination in case of febrile or acute disease. Congenital or acquired immune deficiency impairing cellular immunity including immunosuppressive therapies eg, chemotherapy & high-dose systemic corticosteroids. Symptomatic or asymptomatic HIV-infected patient. Pregnancy & lactation.
Special Precautions
History of serious or severe reaction w/in 48 hr of previous vaccine inj. Not to be inj intravascularly. Treatment w/ high-dose systemic corticosteroids given ≥14 days should be administered for ≥1 mth before vaccination. Not recommended in childn <9 mth.
Adverse Reactions
Fatigue, malaise, inj site pain; headache; myalgia. Feeling hot, chills, inj site erythema, pruritus, swelling & bruising; dizziness; arthralgia; diarrhoea, nausea, abdominal pain, vomiting; pharyngolaryngeal pain, dyspnea, rhinorrhea, cough, wheezing, nasal congestion; rash. Childn: Somnolence; inconsolable crying; loss of appetite.
Drug Interactions
Vaccination must not be performed w/in 6 wk & not w/in 3 mth of Ig inj or Ig-containing blood products eg, blood or plasma to avoid neutralisation of attenuated viruses.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07BA03 - encephalitis, Japanese, live attenuated ; Belongs to the class of encephalitis viral vaccines.
Imojev vaccine (inj) (vial)
0.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in